Therapeutics in Pediatric Diseases
Hakan Onur (Author)
Release Date: 2024-02-12
Gene therapy is a treatment method that involves the alteration, correction or replacement of diseased genes in order to treat genetic diseases or alleviate their symptoms. Gene therapy in children stands out as a promising approach, especially in the treatment of inherited genetic diseases. This therapy aims to correct the source of the disease by [...]
Media Type
Buy from
Price may vary by retailers
Work Type | Book Chapter |
---|---|
Published in | Gene Therapy |
First Page | 65 |
Last Page | 81 |
DOI | https://doi.org/10.69860/nobel.9786053358824.4 |
Page Count | 17 |
Copyright Holder | Nobel Tıp Kitabevleri |
License | https://nobelpub.com/publish-with-us/copyright-and-licensing |
Gene therapy is used especially in the treatment of the following diseases in children: Inherited Genetic Diseases: Diseases such as cystic fibrosis, Duchenne muscular dystrophy, haemophilia. Metabolic Disorders: Metabolic diseases such as phenylketonuria.
Neurological Diseases: Motor neurone diseases such as SMA (spinal muscular atrophy). Gene therapy in children has great potential in the treatment of genetic diseases. With the advancement of technology, safer and more effective treatment methods are expected to be developed. However, overcoming the ethical and financial challenges in this field is important for gene therapy applications to reach a wider audience.
Hakan Onur (Author)
MD, Assistant Professor, Uskudar University
https://orcid.org/0000-0003-4972-3878
3Assistant Professor Hakan Onur graduated from Uludağ University Faculty of Medicine in 1992. In 2001, he received his specialization in Pediatrics from Dicle University Faculty of Medicine. He worked at Diyarbakır Children’s Hospital between 2001-2011. Since 2011, he has been working at Memorial Private Diyarbakır Hospital until today and in 2023, he continues his academic activities as an Assistant Professor at Üsküdar University Faculty of Medicine, Department of Pediatrics. He has studies on pediatric infectious diseases, child development and childhood immunizations in national and international meetings and journals.
Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 –an update. J. Gene Med. 2007;9:833–42.
Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012 -an update. J. Gene Med. 2013 Feb 27;15(2):65-77.
Somia N, Verma IM. Gene therapy: trials and tribulations. Nat. Rev. Genet. 2000 Nov;1:91–9.
Kaufmann P, Pariser AR, Austin C. From scientific discovery to treatments for rare diseases‐the view from the National Center for Advancing Translational Sciences‐Office of Rare Diseases Research. Orphanet J Rare Dis 2018;13:196.
Desnick RJ, Schuchman EH. Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges. Annu Rev Genomics Hum Genet 2012;13:307‐35.
Concolino D, Deodato F, Parini R. Enzyme replacement therapy: Efficacy and limitations. Ital J Pediatr 2018;44(Suppl 2):120.
Chen HH, Sawamoto K, Mason RW, Kobayashi H, Yamaguchi S, Suzuki Y, et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet 2019;64:1153‐71.
Logan AC, Lutzko C, Kohn DB. Advances in lentiviral vector design for genemodification of hematopoietic stem cells. Curr. Opin. Biotechnol. 2002;13:429–36.
Griffin JA. Recombinant DNA – potential for gene therapy. Am. J. Med. Sci. 1985; 289:98–105.
Wiedemann A, Oussalah A, Jeannesson É, Guéant JL, Feillet F. Phenylketonuria, from diet to gene therapy. Med Sci 2020;36(8-9):725-734.
Sudhakar V, Richardson RM. Gene therapy for neurodegenerative diseases Neuro- therapeutics 2019;16(1):166-175.
Gaspar HB, Cooray S, Gilmour KC, et al. Long‐term persistence of a polyclonal T cell repertoire after gene therapy for X‐linked severe combined immunodeficiency. Sci Transl Med. 2011;3(97)
Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus‐ associated virus vector‐mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357‐2365.
Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358:2231‐2239.
Cartier N, Hacein‐Bey‐Abina S, Bartholomae CC, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X‐linked adrenoleu-kodystrophy. Science. 2009;326:818‐823.
Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126‐129.
Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with meta- static synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY‐ESO‐1. J Clin Oncol. 2011;29:917‐924.
Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor‐ modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725‐733.
Sadelain M. CAR therapy: the CD19 paradigm. J Clin Invest. 2015;125:3392‐3400.
Ramos CA, Heslop HE, Brenner MK. CAR‐T cell therapy for lymphoma. Annu Rev Med. 2016;67:165‐183.
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371: 1507‐1517.
Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor‐ modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509‐1518.
Hildt E. Human germline interventions-think first. Front Genet 2016;7:81.
Nóbrega C, Mendonça L, Matos CA. Gene therapy strategies: Gene augmentation. A Handbook of Gene and Cell Therapy. Springer; 2020. p. 117‐26.
US Food and Drug Administration. FDA Approval Brings First Gene Therapy to the United States. CAR T‐Cell Therapy Approved to Treat Certain Children and Young Adults with B‐Cell Acute Lymphoblastic Leukemia. US Food and Drug Administra- tion Newsroom Website: Press Release 30 August 2017. https:// www.fda.gov/ New-sEvents/News- room/PressAnnouncements/ucm574058.htm [3 April 2018]
Clement N, Grieger JC. Manufacturing of recombinant adeno‐ associated viral vectors for clinical trials. Mol Ther Methods Clin Dev. 2016;3.16002
Kohn, D.B., M.S. Hershfield, J.M. Puck, A. Aiuti, A. Blincoe, H.B. Gaspar, L.D. Notarangelo, and E. Grunebaum. Consensus approach for the management of severe combined immune deficiency caused by ade- nosine deaminase deficiency. J. Allergy Clin. Immunol. 2019;143:852–863.
Cicalese, M.P., F. Ferrua, L. Castagnaro, R. Pajno, F. Barzaghi, S. Giannelli, F. Dioni- sio, I. Brigida, M. Bonopane, M. Casiraghi, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficien- cy. Blood. 2016;128:45–54.
Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA‐SCID, the first marketing approval of an. EMBO Mol Med 2017;9:737‐40.
30. Pike-Overzet, K., C. Baum, R.G. Bredius, M. Cavazzana, G.J. Driessen, W.E. Fibbe, H.B. Gaspar, R.C. Hoeben, C. Lagresle-Peyrou, A. Lankester, et al. Successful RAG1-SCID gene therapy depends on the level of RAG1 expression. J. Allergy Clin. Immunol. 2014;134:242–243.
Punwani, D., M. Kawahara, J. Yu, U. Sanford, S. Roy, K. Patel, D.A. Carbonaro, A.D. Karlen, S. Khan, K. Cornetta, et al.Lentivirus Mediated Correction of Artemis-Deficient Severe Combined Immunodeficiency. Hum. Gene Ther. 2017;28:112–124.
Vantil NP., Sarvari R., Visser J., Hauer C., Lagresle-Peyrou G., van der Velden, et al. Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentivi-ral gene therapy demonstrate autoimmune Omennlike syndrome. J. Allergy Clin. Im- munol 2014;133:1116–1123.
CorbacıogluS., Frangoul H., Locatelli F., Hobbs W., Walters M. Defining curative endpoints for transfusion-dependent beta thalassemia in era of gene therapy ande gene editing. Am J Hematol. 2024;15;99(3):422-429.
Locatelli F., Thompson AA., Kwaiatkowski JL., Porter JB., Trasher AJ., HongengS., et al. Betibeglogene Autotemcel Gene Therapy for Beta 0/Beta 0 Genotype Beta Thalassemia. New Engl J Med. 2022;3;386(5):415-427.
Bennett J. Gene therapy for color blindness N Engl J Med 2009;361:2483-4
Mancuso K, Hauswirth WW, Li Q, et al. Gene therapy for red-green colour blindness in adult primates. Nature 2009;461:784-7
El Moussawi ZE, Boueiri M, Al-Haddad C. Gene therapy in color vision deficiency: a review. Int Ophthalmol 2021;41:1917-127.
Wenger DA, Rafi MA, Luzi P, et al. Krabbe disease: genetic aspects and progress toward therapy. Mol Genet Metab 2000;70:1
Duffner PK, Barczykowski A, Jalal K, et al. Early infantile Krabbe disease: results of the World Wide Krabbe Registry. Pediatr Neurol 2011;45:141–8
Bradbury AM, Rafi MA, Bagel JH, et al. AAVrh10 gene therapy ameliorates central and peripheral nervous system disease in canine globoid cell leukodystrophy (Krabbe disease). Hum Gene Ther 2018;29:785–801.
Bradbury AM, Bagel JH, Nguyen D, et al. Krabbe disease successfully treated via monotherapy of intrathecal gene therapy. J Clin Invest 2020;130:4906–4920.
Hordeaux J, Jeffrey BA, Jian J, et al. Efficacy and safety of a Krabbe disease gene therapy. Hum Gene Ther 2021;33:499–517.
Arnold ES, Fischbeck KH: Spinal muscular atrophy. Handb Clin Neurology 2018;148:591-601.
Kolb SJ, Kissel JT: Spinal muscular atrophy. Neurol Clin 2015;33:831-46.
D’Amico A, Mercuri E, Tiziano FD, et al. Spinal muscular atrophy. Orphanet J Rare Dis 2011; 6:71.
Nicolau S, Waldrop MA, Connolly AM, et al. Spinal muscular atrophy. Semin Pediatr Neurol. 2021;37:100878.
Mendell JR, Al-Zaidy S, Shell R, et al: Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713-1722, 2017
Al-Zaidy S, Pickard AS, Kotha K, et al. Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol 2019;54:179-85.
Gabel I., Moreno J., “Genome Editing, Ethics, and Politics,” (in eng), AMA J Ethics 2019;21:1105-1110.25. US Food and Drug Administration. FDA Approval Brings First Gene Therapy to the United States. CAR T‐Cell Therapy Approved to Treat Certain Children and Young Adults with B‐Cell Acute Lymphoblastic Leukemia. US Food and Drug Administra- tion Newsroom Website: Press Release 30 August 2017. https:// www.fda.gov/ New-sEvents/News- room/PressAnnouncements/ucm574058.htm [3 April 2018]
onix_3.0::thoth | Thoth ONIX 3.0 |
---|---|
onix_3.0::project_muse | Project MUSE ONIX 3.0 |
onix_3.0::oapen | OAPEN ONIX 3.0 |
onix_3.0::jstor | JSTOR ONIX 3.0 |
onix_3.0::google_books | Google Books ONIX 3.0 |
onix_3.0::overdrive | OverDrive ONIX 3.0 |
onix_2.1::ebsco_host | EBSCO Host ONIX 2.1 |
csv::thoth | Thoth CSV |
json::thoth | Thoth JSON |
kbart::oclc | OCLC KBART |
bibtex::thoth | Thoth BibTeX |
doideposit::crossref | CrossRef DOI deposit |
onix_2.1::proquest_ebrary | ProQuest Ebrary ONIX 2.1 |
marc21record::thoth | Thoth MARC 21 Record |
marc21markup::thoth | Thoth MARC 21 Markup |
marc21xml::thoth | Thoth MARC 21 XML |